Abstract
Objective: To investigate the molecular phenotype of the AIDS-onset delaying polymorphism in CXCL12β 3UTR (rs1801157). Methods: The 3UTRs of the CXCL12β isoform containing the A or G polymorphic variants were cloned downstream of the Luciferase gene under the control of the CXCL12 promoter. The plasmids were transfected in U373 and LC5 cells and the polymorphism phenotype was evaluated in terms of Luciferase activity and mRNA stability. Results: The 3A genotype compared to 3G leads to an increased luciferase activity in unstimulated and PMA+Ionomycin treated cells both in astrocytes (p= 0,0002, p = 0,02) and fibroblasts (p = 0,002, p = 0,03). The mRNA containing the 3A variant have two-fold longer half-life compared to the 3G variant (p = 6,99E-7). Conclusions: CXCL12β 3A polymorphism, previously associated with resistance to AIDS progression and other diseases, leads to increased levels of CXCL12 mRNA, the results presented here demonstrate that this effect is a consequence of an enhanced mRNA stability. Our data contribute to characterize the CXCL12 as a potential pharmacological target in AIDS, autoimmune diseases and cancer.
Keywords: CXCL12, mRNA stability, AIDS, rs1801157, UTR
Current HIV Research
Title: Molecular Phenotype of CXCL12β 3UTR G801A Polymorphism (rs1801157) Associated to HIV-1 Disease Progression
Volume: 7 Issue: 4
Author(s): Carelia Garcia-Moruja, Patricia Rueda, Carmen Torres, Jose Alcami, Francisco Luque and Antonio Caruz
Affiliation:
Keywords: CXCL12, mRNA stability, AIDS, rs1801157, UTR
Abstract: Objective: To investigate the molecular phenotype of the AIDS-onset delaying polymorphism in CXCL12β 3UTR (rs1801157). Methods: The 3UTRs of the CXCL12β isoform containing the A or G polymorphic variants were cloned downstream of the Luciferase gene under the control of the CXCL12 promoter. The plasmids were transfected in U373 and LC5 cells and the polymorphism phenotype was evaluated in terms of Luciferase activity and mRNA stability. Results: The 3A genotype compared to 3G leads to an increased luciferase activity in unstimulated and PMA+Ionomycin treated cells both in astrocytes (p= 0,0002, p = 0,02) and fibroblasts (p = 0,002, p = 0,03). The mRNA containing the 3A variant have two-fold longer half-life compared to the 3G variant (p = 6,99E-7). Conclusions: CXCL12β 3A polymorphism, previously associated with resistance to AIDS progression and other diseases, leads to increased levels of CXCL12 mRNA, the results presented here demonstrate that this effect is a consequence of an enhanced mRNA stability. Our data contribute to characterize the CXCL12 as a potential pharmacological target in AIDS, autoimmune diseases and cancer.
Export Options
About this article
Cite this article as:
Garcia-Moruja Carelia, Rueda Patricia, Torres Carmen, Alcami Jose, Luque Francisco and Caruz Antonio, Molecular Phenotype of CXCL12β 3UTR G801A Polymorphism (rs1801157) Associated to HIV-1 Disease Progression, Current HIV Research 2009; 7 (4) . https://dx.doi.org/10.2174/157016209788680543
DOI https://dx.doi.org/10.2174/157016209788680543 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Development of Bruton’s Tyrosine Kinase Inhibitors for Rheumatoid Arthritis
Current Medicinal Chemistry Tuning Immune Suppression in Systemic Autoimmunity with Self-Derived Peptides
Inflammation & Allergy - Drug Targets (Discontinued) Update on Intravenous Immunoglobulins (IVIg) Mechanisms of Action and Off- Label use in Autoimmune Diseases
Current Pharmaceutical Design Cell-free DNA: Characteristics, Detection and its Applications in Myocardial Infarction
Current Pharmaceutical Design Cannabinoids, Immune System and Cytokine Network
Current Pharmaceutical Design HMGB-1 as a Target for Inflammation Controlling
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Vitiligo and Allergic Complications from Orthopaedic Joint Implants: The Role of Benzoyl Peroxide
Recent Patents on Inflammation & Allergy Drug Discovery B-Cell Based Gene Therapy for Autoimmune Diseases
Infectious Disorders - Drug Targets The HLA Region and Autoimmune Disease: Associations and Mechanisms of Action
Current Genomics Immune Aging and Autoimmune Diseases in Children
Current Immunology Reviews (Discontinued) B Lymphocytes, Potent Antigen Presenting Cells for Preferential Expansion of Allo-Reactive FoxP3+ CD4 Regulatory T Cells
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Editorial (Thematic Issue: Biologics in Autoimmune Diseases)
Current Pharmaceutical Biotechnology Synthetic Peptides in the Diagnosis of Systemic Autoimmune Diseases
Current Protein & Peptide Science Nucleic Acid Enzymes as a Novel Generation of Anti-gene Agents
Current Molecular Medicine The Effects of Dehydroepiandrosterone (DHEA) in the Treatment of Depression and Depressive Symptoms in Other Psychiatric and Medical Illnesses: A Systematic Review
Current Drug Targets Color Doppler Ultrasound Assessment of Clinical Activity in Inflammatory Bowel Disease
Current Medical Imaging Introduction from Editor-in-Chief
Current Rheumatology Reviews The Long and Winding Road: Searching for Non-MHC Psoriasis Susceptibility Loci
Current Genomics Mechanisms of Neutrophil-mediated Disease: Innovative Therapeutic Interventions
Current Pharmaceutical Design Immunotherapy-Based Strategies for the Treatment of Autoimmune Diabetes: Searching for the Cure
Current Pharmaceutical Design